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Available online 24 March 2014Abstract There are several challenges to successful implementation of a cell therapy for insulin dependent diabetes derived from
human embryonic stem cells (hESC). Among these are development of functional insulin producing cells, a clinical delivery method
that eliminates the need for chronic immunosuppression, and assurance that hESC derived tumors do not form in the patient. We and
others have shown that encapsulation of cells in a bilaminar device (TheraCyte) provides immunoprotection in rodents and primates.
Here we monitored human insulin secretion and employed bioluminescent imaging (BLI) to evaluate the maturation, growth, and
containment of encapsulated islet progenitors derived from CyT49 hESC, transplanted into mice. Human insulin was detectable by
7 weeks post-transplant and increased 17-fold over the course of 8 weeks, yet during this period the biomass of encapsulated cells
remained constant. Remarkably, by 20 weeks post-transplant encapsulated cells secreted sufficient levels of human insulin to
ameliorate alloxan induced diabetes. Further, bioluminescent imaging revealed for the first time that hESCs remained fully contained
in encapsulation devices for up to 150 days, the longest period tested. Collectively, the data suggest that encapsulated hESC derived
islet progenitors hold great promise as an effective and safe cell replacement therapy for insulin dependent diabetes.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).the minute-to minute precision that islets provide and thisIntroduction
There are 382 million people with diabetes worldwide. All
patients with Type I and approximately 25% of patients with
Type II diabetes require exogenous insulin to survive (Koro et
al., 2004). Unfortunately, insulin injections cannot match⁎ Corresponding author at: Sanford Burnham Medical Research
Institute, 10901 N. Torrey Pines Rd, La Jolla, CA 92037, U.S.A.
E-mail address: pitkin@sanfordburnham.org (P. Itkin-Ansari).
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1873-5061/© 2014 The Authors. Published by Elsevier B.V. This
(http://creativecommons.org/licenses/by-nc-nd/3.0/).disparity leads to debilitating complications (e.g. blindness,
heart disease, kidney failure). Islet transplantation has been
tried with some success. However, the shortage of donor
organ tissue and risks associated with lifelong immunosup-
pression limit islet transplantation to only the most severely
impacted brittle diabetics (Ryan et al., 2006). Thus, successful
development of a universal cell therapy to treat diabetes
requires a renewable, safe source of glucose responsive
human islet cells and a means for their delivery without the
use of chronic immunosuppression.is an open access article under the CC BY-NC-ND license
808 K. Kirk et al.Human embryonic stem cells (hESCs) represent an excellent
starting material for the generation of numerous islet cells.
Methods for the production of hESC-derived pancreatic epithe-
lium (hESC-PE) have been described (D'Amour et al., 2006;
Kroon et al., 2008; Kelly et al., 2011; Schulz et al., 2012; Jiang
et al., 2007; Shim et al., 2007; Rezania et al., 2012; Ku et al.,
2004; Van Hoof et al., 2009; Bruin et al., 2013; Rezania et al.,
2013; Aguayo-Mazzucato and Bonner-Weir, 2010; Mayhew and
Wells, 2010; Zhang et al., 2009; Cho et al., 2012). Recently
multi-step protocols were developed and optimized to differ-
entiate the CyT49 hESC line from the naïve state through key
stages of pancreatic development (D'Amour et al., 2006; Kroon
et al., 2008; Kelly et al., 2011; Schulz et al., 2012); definitive
endoderm, foregut, and pancreatic epithelium, that efficiently
generates functional β-cells in vivo. When transplanted under
the kidney capsule of immunocompromised mice these cells
develop into functional islets in vivo over the course of 7 to
16 weeks. Notably, the CyT49 hESC line is amenable to the type
of scalable processes ultimately needed for clinical use (Schulz
et al., 2012).
Cellular encapsulation has been investigated as a
means of reducing and/or eliminating the need for chronic
immunosuppression by protecting transplanted cells from
direct contact with host immune effector cells. Previously,
we and others have demonstrated that a planar pouch-like
encapsulation device (TheraCyte, Inc.), featuring a bilaminar
polytetrafluoroethylene (PTFE) membrane system, provides
immunoprotection to transplanted cells in mice and in primates
(Brauker et al., 1995; Carr-Brendel et al., 1997; Sweet et al.,
2008; Loudovaris et al., 1999; Tatarkiewicz et al., 1999; Rafael
et al., 2003; Tibell et al., 2001; Lee et al., 2009; Tarantal et al.,
2009; Kumagai-Braesch et al., 2013). However, the clinical use
of hESC-derived cell products may yet be hampered by safety
concerns over the potential growth of teratomas developing
from contaminating pluripotent hESCs, particularly in immu-
nocompromised patients. Thus, a durable and retrievable
encapsulation device might also serve as a platform for
safely administering hESC-derived therapies. Importantly,
we recently found that the TheraCyte device is extremely
durable and maintains integrity after freezing (Yakhnenko et
al., 2012). Thus, in addition to immunoprotection the device
may provide full containment of grafts, but this has yet to be
formally tested.
Previously we showed that primary islet progenitor
cells from the human fetal pancreas, encapsulated in the
TheraCyte device, matured into fully functional islets in vivo
over the course of 3 to 5 months (Lee et al., 2009). This study
was the first to demonstrate that direct contact between
transplanted islet progenitors and host tissue is not required
for β-cell maturation. The primary human cells exhibited a
robust and sustained response in vivo capable of ameliorating
alloxan induced diabetes, suggesting that encapsulated stem
cell derived islet progenitors might similarly mature and
function in vivo (Lee et al., 2009).
The present study was designed to investigate the spatio-
temporal kinetics of cellular engraftment and the maturation
dynamics of encapsulated CyT49 hES-PE cells. We find that
encapsulated CyT49-derived PE attains full physiological
function in vivo, contributing to glucose homeostasis following
alloxan-induced diabetes, consistent with a recent finding
with H1 hESC (Bruin et al., 2013). Moreover, bioluminescent
imaging (BLI) of luciferase-expressing CyT49 cells (CyT49-luc)reveals for the first time that encapsulated islet progenitors
acquire glucose-responsiveness without a significant change
in biomass. Further, BLI shows that the TheraCyte device
provides long-term containment of transplanted hES cells
without evidence of cell escape. Collectively, the findings
suggest that encapsulated hESC-derived PE holds great
promise for the treatment of diabetes.
Material and methods
hESC culture and lentiviral transduction
The CyT49 hESC cell line was cultured as previously described
(Schulz et al., 2012). Briefly, the cells were maintained in a
Xeno-free growth media (XF HA) consisted of DMEM/F12
containing GlutaMAX (Life Technologies) supplemented
with 10% (v/v) of Xeno-free KnockOut Serum Replacement
(Life Technologies), 1% (v/v) non-essential amino acids (Life
Technologies), 0.1 mM 2-mercaptoethanol (Life Technolo-
gies), 1% (v/v) penicillin/streptomycin (Life Technologies),
10 ng/mL heregulin-1β (Peprotech) and 10 ng/mL activin A
(R&D Systems). Cell culture was performed in humidified
incubators at 37 °C and 8% CO2. The subline constitutively
expressing luciferase, CyT49-luc, was generated by trans-
ducing cells with a self-inactivating (SIN) lentivirus carrying
firefly luciferase driven by the human elongation factor 1
alpha subunit (a kind gift from Dr. Nik Somia). At a multiplicity
of infection (MOI) of 30 approximately 85% of cells were
transduced as determined by immunostaining and cell sorting
and the entire population was expanded for study. CyT49 and
CyT49-luc cells were directed through key stages of pancreatic
development, including definitive endoderm, primitive gut
tube, posterior foregut, and pancreatic epithelium at ViaCyte
according to previously published protocols (D'Amour et al.,
2006; Kroon et al., 2008; Kelly et al., 2011; Schulz et al.,
2012). For differentiation induction, the aggregates were
pooled and washed with PBS prior to resuspending in day 0
differentiation media containing RPMI, ITS (1:1000), activin A
(100 ng/ml) and Wnt3a (50 ng/ml). Thereafter, media was
changed daily as follows: (day 1—RPMI with 0.2% vol/vol FBS,
ITS (1:1000) and activin A (100 ng/mL), day 2—RPMI with 0.2%
FBS, ITS (1: 1000), KGF (25 ng/mL) and TBF inhibitor IV
(2.5 μM), day 3—RPMI with 0.2% FBS, ITS (1:1000) and KGF
(25 ng/mL), day 5—DMEM (HiGlucose) with 1% B27 supple-
ment, KAAD-cyclopamine (0.25 μM), TTNPB (3 nM), KGF
(50 mg/mL), EGF (50 ng/mL) and noggin (50 ng/mL), and
day 8—DMEM (HiGlucose) with 1% B27 supplement, KGF
(50 mg/mL), EGF (50 ng/mL) and noggin (50 ng/mL) by gentle
aspiration from the well and replacement. Luciferase expres-
sion did not alter the efficiency of generating hES-PE in vitro
or cell maturation in vivo.
Encapsulation and transplantation
Polytetrafluoroethylene (PTFE), bilaminar Theracyte™ devices
with nominal internal volumes of 5 or 20 μL were employed.
Under sterile conditions, CyT49 or CyT49-luc hESC (naïve or
differentiated in vitro to pancreatic epithelium) clusters were
loaded into devices at 1.5–3 × 105 cells/μL. Device ports were
sealed with medical-grade silicon adhesive and trimmed. Mice
were anesthetized with isofluran. After a dorsal midline
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hemostat and the devices were implanted subcutaneously. The
incision was closed by surgical suture or surgical clips. SCID/
beige mice were employed for all studies because 1) the
encapsulation device does not protect cells from xenograft
rejection and 2) so that if cells escaped from the device they
would not be destroyed by the animal's immune system and
could be detected by BLI. All studies were performed in
accordance with UCSD and Sanford-Burnham Medical Research
Institute IACUC regulations.Bioluminescent imaging
For in vivo imaging, anesthetized mice were injected intraper-
itoneally with filtered 150 mg/kg D-luciferin (Xenogen) in
sterile PBS, placed in the imaging chamber and scanned using
the IVIS Spectrum imaging platform (PerkinElmer). To quantify
luciferase expression in vitro, encapsulated or unencapsulated
cells were incubated in culture media containing 150 μg/mL
luciferin. Data were analyzed with Living Image Software
(PerkinElmer) by delimiting a constant region of interest
(ROI, fixed area) around the device and quantifying total
radiance in photon/sec/cm2/sr. We previously demonstrat-
ed that subcutaneous placement of a cell filled device
results in approximately 50 fold attenuation of signal
(Tarantal et al., 2009).GSIS
Starting from approximately 35 days, graft function was
assessed by performing measurement of serum human
C-peptide in response to glucose administration. Prior
to the GSIS assay, mice were fasted for approximately
10–18 h. Glucose was administered via intraperitoneal
injection of a 30% dextrose solution at a dose of 3.0 g/kg
body weight, and blood was collected prior to (fasting) and
at multiple time points after glucose administration.
Blood samples of approximately 20–40 μL were collected
from the tail vein and transferred to microtainer tubes
(BD Biosciences) containing blood/serum separation gel.
Serum was collected after spinning tubes according
to manufacturer's directions. The ELISA used for human
C-peptide (Ultrasensitive Human C peptide ELISA (Mercodia)
was the same as used previously (Lee et al., 2009). Multiple
dilutions of samples were tested to assure values within
the range of the calibration curve. Baseline C-peptide was
obtained before glucose challenge. The stimulation index (SI)
was calculated as the C-peptide released at 60 min following
glucose injection divided by the basal level.Alloxan treatment of mice
Destruction of murine but not human β-cells was achieved by
intravenous administration of a single dose of 90 mg/kg
alloxan (Sigma, MO) as previously described (Lee et al.,
2009; Tyrberg et al., 2001). Blood glucose was measured
via the tail vein samples using a handheld (Alpha-Trak
glucometer, Abbott labs). The fasting blood glucose was
monitored daily for up to 23 days.Immunostaining of explanted devices
At the termination of experiments, mice were sacrificed by
an overdose of pentobarbital or cervical dislocation and
devices and surrounding tissue were dissected and retrieved
for immunofluorescent analysis of grafts. Devices were fixed
in 4% paraformaldehyde overnight at 4 C, dehydrated and
processed for paraffin embedding and sectioning. Samples
were sliced on a microtome at a thickness of 5 microns.
Engrafted cells were immunostained for insulin (Santa Cruz),
CK19 (DAKO), and glucagon (BD and Sigma). Counterstain
was carried out with DAPI4′, 6-diamidino-2-phenylindole
(DAPI) (AppliChem). Images were captured using a conven-
tional inverted microscope (Olympus, PlanFl 40/0.60, Center
Valley, PA) or a confocal microscope (Bio-Rad Laboratories
Inc., CA) equipped with krypton/argon laser.Statistical analysis
Data are expressed as average ± standard error of the mean
(SEM). The statistical significance of the differences between
groups was analyzed by Student's t test.Results
Maturation of encapsulated hES cells occurs without
an increase in cellular biomass
Here we investigated whether encapsulated CyT49 hES-PE
cells can mature in vivo and if so, whether this process is
associated with growth. Circulating human C-peptide, mea-
sured to assess islet function of the graft, was first detectable
at approximately 7 weeks post-transplant and continued to
rise through week 15. Importantly, in vitro differentiation to
pancreatic epithelium was absolutely required for develop-
ment of cells expressing human C-peptide. As shown in
multiple cohorts of SCID/beige mice transplanted subcutane-
ously with 5 μL devices, no human C-peptide was detected in
mice transplanted with naïve CyT49 cells (Fig. 1A).
In order to monitor survival and expansion dynamics
of encapsulated hES-PE during the maturation process we
generated a stable derivative line of CyT49 hESC which
expresses luciferase (CyT49-luc). To drive luciferase expres-
sion we employed the elongation factor 1a (EF1α) promoter
because it is constitutively expressed and has been used to
express luciferase in both developing and mature islets
(Londrigan et al., 2007). Previously, we showed in both mice
and non-human primates that cell encapsulation does not
interfere with bioluminescent imaging of luciferase expres-
sion (Lee et al., 2009; Tarantal et al., 2009). Indeed, here
we found a nearly identical linear relationship between
cell volume and bioluminescent signal in encapsulated and
unencapsulated CyT49-luc cells (Supp Fig. 1). Moreover,
others have shown a linear relationship between cell number
and BLI signals above 1 × 1010. Thus, we expect ample room
for detection of cell growth if it occurred.
In a series of transplants with CyT49-luc-PE in 20 μL
devices, a 17 fold increase in maximal C-peptide was observed
between 7 and 15 weeks (Fig. 1B). In three cohorts of 6 mice
each, bioluminescent imaging revealed for the first time that
Figure 1 β-cell maturation in vivo requires in vitro differentiation to pancreatic epithelium but not cell growth. A) Undifferentiated
(Undiff) CyT49 cells or cells differentiated in vitro to pancreatic epithelium (Groups 1, 2, 3) were encapsulated in 5 μL devices and
transplanted subcutaneously in SCID/beige mice. Circulating human C-peptide was detectable by approximately 7 weeks in Groups 1, 2,
and 3 and was measured at multiple time points over the course of 21 weeks, n = 3 for each group. B) hESC-PE from CyT49-luc cells was
encapsulated in 20 μL devices and transplanted in 3 cohorts of 6 mice each. From approximately week 7 to week 15 following
transplantation both luciferase (red) and human C-peptide (blue) were monitored. Data are shown as average +/−SEM.
Figure 2 Human ESC-derived pancreatic cells secrete human insulin levels in the nanomolar range and ameliorate diabetes in mice.
CyT49-luc derived PE was encapsulated in 20 μL devices. A) At 20 weeks post-transplant cells exhibited high levels of glucose
stimulated human C-peptide. B) Alloxan treated mice develop life threatening diabetes within 48 to 96 h (green) and most must be
sacrificed by day 4, n = 9. However, in mice transplanted 5 months prior to alloxan with encapsulated CyT49-luc derived PE there is
significant amelioration of diabetes (red). Normoglycemic controls include animals transplanted with encapsulated CyT49-luc PE
which were not treated with alloxan (blue) and untreated animals (black bar), n = 3–5 per group and the experiment has been
repeated. C–E. Immunofluorescent staining of devices harvested after amelioration of diabetes, immunostained for insulin (green)
and either CK19 (red) or glucagon (red). C. The graft is comprised of a high percentage of insulin positive cells and also contains small
ductal structures (CK19), 100× original magnification. Note that device membranes autofluoresce red and the graft has separated
during processing. D. High power view of graft immunostained for insulin and CK19, 1200× E. High power view of insulin and glucagon
staining, 1200×. Note that single cells in the graft are not positive for both hormones.
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maturation process. Therefore, although there may be some
cell turnover, there is no net increase in steady state mass,
indicating that hES-PE maturation into islets does not require
significant growth.
Human ES cells develop insulin levels in the
nanomolar range and ameliorate diabetes in mice
The hallmark of a mature β-cell is regulated insulin secretion
in response to glucose. To evaluate the function of encapsu-
lated CyT49-luc cells at 20 weeks post transplant, human
C-peptide was measured after a 5 hour fast and subsequently,
60 min following a glucose challenge. Basal human C-peptide
was detectable in all animals transplanted with 20 μL devices.
Moreover, C-peptide increased significantly following glucose
injection, with a stimulation index (glucose stimulated/basal)
ranging from 4.5 to 20.9 (Fig. 2A). Many animals transplanted
with 20 μL devices exhibited maximal C-peptide release in
the 4000 to 5000 pM range, suggesting sufficient levels to
contribute significantly to glucose homeostasis.
Therefore, to further assess the function of encapsulated
CyT49-luc derived islets we analyzed their capacity to
maintain glucose homoeostasis in the face of murine β-cell
destruction. Murine β-cells were eliminated by injection of
alloxan at a dose which is selectively toxic to murine but not
human β-cells (Lee et al., 2009; Tyrberg et al., 2001). Alloxan
rapidly induced diabetes in control animals (without human
cell grafts) as blood glucose rose to 700 mg/dL within 96 h
(Fig. 2B). In contrast, significant preservation of glycemic
control was observed in animals which had been transplanted
with encapsulated CyT49-luc hESC-PE 5 months prior to alloxan
treatment. In these animals blood glucose levels post-alloxan
averaged below 300 mg/dL for 23 days, the longest period
tested. Upon sacrifice, analysis of the pancreases confirmed
that the murine β-cells had been destroyed by alloxan (Supp
Fig. 2). Thus, the data show that encapsulated CyT49-luc hESC
derived insulin producing cells are functional in vivo.
Immunofluorescent staining of explanted devices revealed
large areas of insulin positive cells in the grafts, as expected
from C-peptide data (Fig. 2). Importantly, endocrine cells
expressed either insulin or glucagon, but not both, signifying
that progenitor cells in the device had matured along distinct
endocrine lineages. Interestingly, as we previously found with
encapsulated primary human fetal pancreas tissue, explants
also contained some CK19 positive ductal cells (Lee et al.,
2009) (Fig. 2). However, acinar tissue was not detected by
amylase immunostaining. Thus, encapsulated CyT49 derived
PE underwent predominantly endocrine differentiation. In
contrast to results obtained with 20 μL devices, some animals
transplanted with 5 μL devices did not exhibit human
C-peptide levels above 200 picomolar. In these animals, the
graft did not efficiently control glycemia after alloxan
treatment (Supp Fig. 3).
Assessment of cell containment inmacroencapsulation
devices
A major concern for the successful implementation of a
cell therapy for insulin dependent diabetes derived from
hESCs is the potential for growth of unwanted cell types andthe formation of teratomas. A device which fully contains
cells could be critical for clinical use. In our previous
studies with encapsulated primary human pancreatic tissue
or aggressively growing human cell lines, we did not find
evidence of cell escape in immunocompromised mice, a host
in which rogue cells could become established tumors
(Lee et al., 2009; Itkin-Ansari et al., 2003). Consistent with
those findings, here visual inspection of 38 immunocompro-
mised mice transplanted with encapsulated CyT49 cells
(naïve or pancreatic epithelium) revealed no evidence of
tumors. To more rigorously investigate the possibility of cell
escape we employed whole body BLI (n = 21). Due to its
sensitivity BLI is routinely used to detect micrometastases in
animals and in some cases has detected a single cell in vivo
(Jenkins et al., 2003; Kim et al., 2010; Volk-Draper et al.,
2012; Xie et al., 2012). Mice were followed for as long as
154 days with the finding that BLI signal was limited to the
encapsulation device (Fig. 3). We could reliably load as few
as 3 clusters (approximately 1500 cells) of cells into devices
and based upon the signal obtained, we estimate that signal
from as few as 30 cells could be detected above background
(Supp Fig. 4). Macroscopic and histologic examination of
tissue surrounding explanted devices was performed to
ensure that there was not a tumor adjacent to, or under,
the encapsulation device which might have been masked by
signal from encapsulated cells. Finally, no host cells were
identified within the lumens of the encapsulation devices,
serving as additional evidence of the devices remaining fully
intact. Collectively our results suggest that the encapsula-
tion device efficiently limits direct contact between graft
and host cells and prevents graft cell escape into the host.Discussion
Here, we demonstrate the efficient development of functional
insulin-producing grafts derived from encapsulated CyT49-luc
hESC-PE. Moreover, we find that maturation occurs without an
increase in cell biomass and that encapsulated cells remain fully
contained inside devices. An early attempt to transplant a
preparation of encapsulated CyT49 cells was not successful
(Matveyenko et al., 2010); however, since the time of that study
several refinements to the differentiation protocol have been
made (D'Amour et al., 2006; Kroon et al., 2008; Kelly et al.,
2011; Schulz et al., 2012). Our results withmultiple preparations
of cells, with and without luciferase expression, were highly
reproducible in multiple cohorts of animals. Thus, the data
presented here together with a recent study using the H1 hESC
line (Bruin et al., 2013) suggest that development of functional
islets from encapsulated stem cell derived PEmay be universally
applicable across hESC lines. We also find for the first time that
cells in 5 μL devices do not efficiently treat alloxan induced
diabetes and this has important implications for extrapolation to
device design/cell mass required for treating humans.
Islet development from encapsulated hESC-PE mirrors our
previous findings with primary human fetal pancreas tissue in
multiple ways. In both cases maturation to functional islets
occurred efficiently inside encapsulation devices, signifying
that cell–cell connections between transplant and host are
not required. Further, these studies with encapsulated cells
(Lee et al., 2009; Tarantal et al., 2009; Itkin-Ansari et al.,
2003) point to the suitability of the subcutaneous site for
Figure 3 Cell containment within the TheraCyte encapsulation device. Representative heat maps of photon emission from a cohort
of 3 mice implanted with encapsulated CyT49-luc PE cells for 154 days reveal that signal remains localized to encapsulation device. A
total of 21 animals were imaged for 60 to 154 days.
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clinical translation given the ease of access afforded by the
subcutaneous space for implantation and for retrieval.
Moreover, subcutaneously placed devices may also be ame-
nable to imaging techniques that have a short depth range,
such as high frequency ultrasound, to follow graft survival.
Fortunately for translation of these findings, differentiation of
encapsulated hESC-PE favors development of the endocrine
compartment, not the exocrine compartment which normally
comprises 98% of the pancreas. Some CK19 positive cells were
found in encapsulated primary human fetal pancreas cells
(Lee et al., 2009) and in these hES cell grafts. We did not find
evidence of amylase positive acinar cells although it is possible
that a small number of amylase−/trypsin+ cells reside in
grafts as observed by Rezania et al. (Rezania et al., 2012).
In our earlier studies with encapsulated primary islet
progenitors a portion of cells expressed the proliferation
marker Ki67 (Lee et al., 2009), suggesting that some cell
growthmay be required for cell maturation. To our knowledge
this basic developmental question has never been answered.
In order to track cell number longitudinally in vivo, we
used highly sensitive bioluminescent imaging. We previously
showed that luciferase accurately correlates with changes in
cell volume in studies with encapsulated cells in mice and
monkeys (Lee et al., 2009; Tarantal et al., 2009) and others
have shown a linear relationship between cell number and
BLI signal as high as 5 × 1010 (Xie et al., 2012). Therefore, we
generated a stable CyT49 sub-line expressing firefly luciferase
from the human EF1α promoter. This promoter is constitu-
tively active and led to robust luciferase expression in hES-PE.
Moreover the EF1α promoter has been used to drive luciferasein both neonatal and mature islets (Londrigan et al., 2007).
Nevertheless, it is formally possible that EF1α promoter
activity was not identical among all cell types. As we had
previously found with luciferase expressing murine cells,
encapsulation did not interfere with luciferase detection, and
the signal intensity correlated well with cell number. Remark-
ably, during the period of 7–15 weeks when a significant
increase in circulating insulin was observed, we observed no
increase in steady state cell mass. One cohort of animals
exhibited a drop in luciferase signal at day 60, but this was not
observed in all groups. Thus, while some cell turnover may
occur during the maturation process, if so, it is likely matched
by cell death. Therefore, we provide the first evidence that
growth is not required during maturation of human pancreatic
epithelium into functional islets.
An important concern regarding stem cell based therapies
is the potential for unwanted cell growth. In a previous
study we showed that the TheraCyte encapsulation device
is durable enough to withstand freezing without evidence
of cell escape, suggesting that once cells are sealed in
devices they will remain confined (Yakhnenko et al., 2012).
Nevertheless, to more formally address this issue, BLI was
used for spatial and temporal monitoring of encapsulated
CyT49-luc cells in immunocompromised animals. Due to
its sensitivity BLI is routinely employed for detection of
micrometastases in animals with large primary tumors
(Jenkins et al., 2003; Volk-Draper et al., 2012). Others
have shown that as few as 3 cells could be detected in vivo
and moreover, that 3 cells could be distinguished from 5
versus 10 versus 50 cells (Kim et al., 2010). Importantly, we
did not find evidence of cell escape in any of 23 engrafted
813Encapsulated human embryonic stem cell derived isletsSCID/beige for up to 154 days, the longest period evaluated.
The data suggest that larger studies to extend these findings
are warranted. Importantly, in the clinical setting of
immunocompetent patients, if a cell escaped from the
encapsulation device, it would presumably be recognized
as foreign and destroyed. Nevertheless, an encapsulation
device which prevents cell escape into the host is desirable
as a safety measure and for retrievability of grafts.Conclusions
The data presented here indicate that in vitro derived hESC-PE
fromCyT49 cells generates glucose responsive insulin producing
cells inside a durable encapsulation device with no increase in
cell mass and without cell escape. Taken together with our
previous studies showing that the encapsulation device is
immunoprotective in mice and primates (Lee et al., 2009;
Tarantal et al., 2009), the data indicates that a combination of
stem cells and encapsulation technology holds promise as a safe
and effective therapy for diabetes. Although generally consid-
ered in the context of T1D, this approach could also provide a
long-term benefit for the large number of patients with insulin
dependent T2D (Koro et al., 2004). Additionally, in patients
with non-insulin dependent T2D, short-term transplants might
preserve endogenous islet mass by relieving stress in fatigued
islets, while patients undertake lifestyle changes. Moreover,
given the robust nature of our findings and the many diseases
for which secreted factors are therapeutic, the combination of
stem cells and encapsulation technology is likely to become an
increasingly compelling approach in medicine.
Supplementary data to this article can be found online at
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